Alpa Laboratories Ltd Stock Price Today (NSE: ALPA)
Fundamental Score
Alpa Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alpa Laboratories Ltd share price today is ₹69.70, up +0.00% on NSE/BSE as of 18 June 2026. Alpa Laboratories Ltd (ALPA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹160.35 (Cr). The 52-week high for ALPA share price is ₹108.30 and the 52-week low is ₹46.10. At a P/E ratio of 8.59x, ALPA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.09% and a debt-to-equity ratio of 0.00.
Alpa Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Alpa Laboratories Ltd share price chart: 2.94% return over the past month. 52-week high ₹108.30, 52-week low ₹46.10.
Alpa Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹69.70 | ₹71.00 | ₹68.30 | ₹69.70 | 11.58K (Cr) | |
| ₹72.50 | ₹73.00 | ₹68.50 | ₹69.70 | 81.14K (Cr) | |
| ₹70.36 | ₹74.80 | ₹69.61 | ₹71.42 | 41.23K (Cr) | |
| ₹70.68 | ₹71.90 | ₹68.33 | ₹70.71 | 12.25K (Cr) | |
| ₹68.10 | ₹71.00 | ₹68.03 | ₹70.68 | 28.65K (Cr) | |
| ₹68.16 | ₹69.99 | ₹67.00 | ₹68.00 | 14.53K (Cr) | |
| ₹71.00 | ₹71.00 | ₹67.00 | ₹69.16 | 8.44K (Cr) | |
| ₹69.50 | ₹69.70 | ₹68.10 | ₹69.56 | 3.77K (Cr) | |
| ₹69.70 | ₹69.70 | ₹66.80 | ₹68.22 | 16.84K (Cr) | |
| ₹69.95 | ₹71.00 | ₹69.00 | ₹69.78 | 4.86K (Cr) |
Alpa Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹72.50 | ₹73.00 | ₹68.30 | ₹69.70 | -3.86% | |
| ₹66.17 | ₹74.80 | ₹66.09 | ₹71.42 | +7.93% | |
| ₹50.65 | ₹72.47 | ₹48.60 | ₹66.18 | +30.66% | |
| ₹66.80 | ₹66.80 | ₹46.10 | ₹46.46 | -30.45% | |
| ₹68.01 | ₹76.18 | ₹64.40 | ₹66.01 | -2.94% | |
| ₹77.85 | ₹80.08 | ₹61.00 | ₹68.14 | -12.47% | |
| ₹78.60 | ₹92.50 | ₹75.00 | ₹77.69 | -1.16% | |
| ₹90.20 | ₹91.86 | ₹75.55 | ₹78.16 | -13.35% | |
| ₹90.00 | ₹93.85 | ₹85.91 | ₹91.57 | +1.74% | |
| ₹95.93 | ₹99.00 | ₹88.02 | ₹88.48 | -7.77% | |
| ₹101.01 | ₹102.55 | ₹90.36 | ₹94.44 | -6.50% | |
| ₹106.40 | ₹108.30 | ₹100.00 | ₹101.01 | -5.07% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play with a busted balance sheet and zero margin for error; avoid before it implodes.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Alpa Laboratories faced scrutiny regarding a significant price movement, prompting the exchange to seek clarification on April 8, 2026. The company's Q3 FY26 results showed a net profit of Cr, a substantial QoQ increase of 1,627.27% from Cr in Q2 FY26, but a concerning 78.65% YoY decline. Revenue for Q3 FY26 stood at Cr, reflecting an 11.09% YoY increase.
CORE STORY (THE REAL GAME)
Alpa Labs is being priced as a deeply troubled micro-cap pharma play attempting a turnaround, but struggling with consistent profitability. The market is hyper-focused on whether they can fix their operational inefficiencies and sustain any profit recovery.
- Q3 FY26 profit recovery is likely unsustainable
- YoY profit decline of 78.65% signals deeper problems
- Micro-cap liquidity risk is too high
- Sustained margin expansion
- Significant order wins
- Successful debt restructuring
- Micro-cap with limited liquidity
- Inconsistent profitability and reliance on non-operating income
- Resignation of Company Secretary/Compliance Officer
FII down 0.01% — not a good sign.
Indian pharma exports are growing, but Alpa Labs isn't benefiting.
Poor. ₹15.17 Cr FCF over 5 years is weak.
Next 3-6 months will determine if Alpa Labs can turn things around, but the odds are stacked against them. Expect continued volatility and potential downside.
Primary Thesis Risk
Inability to improve operational efficiency and manage costs will lead to insolvency.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Alpa Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alpa Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALPA across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.79%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 8.59 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (49.23% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (49.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (121.32x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (57.29%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-98.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 0.35%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Alpa Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Alpa Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Alpa Laboratories LtdAlpa Laboratori...Selected✓ ALPA • 532878 | 55.7/100 | ₹69.70₹70 | ₹160.35₹160.35 | 8.59Average 8.6 Average | 12.09%Average 12.09% Average | 15.79%Good 15.79% Good | 0.00Excellent 0.0 Excellent | 49.23%Excellent 49.23% Excellent | 5.24%Good 5.24% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1798.70₹1799 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6556.50₹6557 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4356.40₹4356 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.50₹1391 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1292.40₹1292 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2267.50₹2268 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1092.90₹1093 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.60₹2321 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.10₹1433 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5322.50₹5323 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Alpa Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for ALPA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹8.01 | ₹118.46 | 14.8x |
| FY 2023 | ₹5.88 | ₹103.30 | 17.6x |
| FY 2022 | ₹6.70 | ₹63.00 | 9.4x |
| FY 2021 | ₹3.45 | ₹79.40 | 23x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Alpa Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ALPA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-98.57%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
49.23%
Compounded annual net profit growth over 5 years
Alpa Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ALPA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Alpa Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Alpa Laboratories Ltd (ALPA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Alpa Laboratories Ltd
About ALPA (Alpa Laboratories Ltd)
Alpa Laboratories Ltd is a dynamic pharmaceutical company rooted in Indore, India, dedicated to the development, manufacturing, and distribution of a diverse range of pharmaceutica...l products. With a history stretching back to its incorporation, the company has steadily cultivated a reputation for quality and reliability within the Indian pharmaceutical landscape. Alpa Laboratories focuses on providing accessible and effective medications, aiming to cater to a broad spectrum of healthcare needs across various therapeutic areas. Their commitment to rigorous quality control and adherence to industry best practices ensures that their products meet the highest standards of safety and efficacy, solidifying their position as a trusted provider in the market. The company's enduring presence speaks to its commitment to innovation and service within the ever-evolving healthcare sector. Alpa Laboratories is characterized by its dedication to producing formulations that cover a wide range of therapeutic segments. This encompasses areas such as pain management, cardiovascular health, and anti-infectives, showcasing the company's breadth and ability to address numerous prevalent health concerns. The company demonstrates an understanding of the healthcare challenges facing India and strives to provide solutions through its comprehensive product portfolio. This diverse offering allows Alpa Laboratories to serve a broad patient base and contribute meaningfully to improved healthcare outcomes across the country. The firm's commitment to expanding its therapeutic reach underscores its ambition to be a significant contributor to the health and well-being of the Indian population. At its core, Alpa Laboratories operates with a vision of enhancing patient lives through access to quality pharmaceuticals. While firmly established in Indore, the company's influence extends across India, reaching patients and healthcare providers alike. Their established infrastructure and distribution network enable them to effectively deliver their products to various markets, ensuring accessibility and timely availability. Alpa Laboratories' steady growth trajectory reflects its focus on sustainable practices, continuous improvement, and a dedication to meeting the evolving needs of the healthcare industry. This unwavering commitment to excellence positions Alpa Laboratories for continued success and growth in the years to come.
Company Details
Key Leadership
ALPA Share Price: Frequently Asked Questions
What is the current share price of Alpa Laboratories Ltd?
Alpa Laboratories Ltd (ALPA) trades at ₹69.70 on NSE and BSE. Market cap ₹160.35 (Cr). Educational data only.
What is the P/E ratio of Alpa Laboratories Ltd?
Alpa Laboratories Ltd has a P/E of 8.59x vs industry average 31.77x.
What is the Bull Run score for Alpa Laboratories Ltd?
Alpa Laboratories Ltd has a Bull Run score of 55.7/100 based on 25+ financial parameters.
Does Alpa Laboratories Ltd pay dividends?
Alpa Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Alpa Laboratories Ltd?
Alpa Laboratories Ltd has ROE of 12.09%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Alpa Laboratories Ltd?
Alpa Laboratories Ltd has debt-to-equity of 0.00.
Is Alpa Laboratories Ltd a good investment?
Bull Run gives Alpa Laboratories Ltd a score of 55.7/100. This is not investment advice — consult a SEBI-registered advisor.